Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting NCT07139548 Sponsor: Guangdong Raynovent Biotech Co., Ltd Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting

NCT07139548
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with type 2 diabetes.
  • People whose HbA1c (a blood test that measures average blood sugar levels over about 3 months) is between 7.0% and 11.5%.
  • People whose Body Mass Index (BMI) is 20 or above at the time of their screening appointment.
  • People whose weight has been stable (within 5% up or down) for at least 12 weeks before their screening appointment.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have type 1 diabetes.
  • People who have serious long-term diabetes complications such as certain eye conditions (including advanced diabetic eye disease or fluid build-up at the centre of the eye) that need urgent treatment.
  • People who have had a serious diabetes-related emergency involving very high blood sugar (such as diabetic ketoacidosis or hyperosmolar hyperglycemic state) in the 24 weeks before joining the trial.
  • People who have had a severe low blood sugar episode in the 12 months before screening, or three or more moderate low blood sugar episodes in the 3 months before screening, or who currently have symptoms related to low blood sugar (confirm with trial site).
  • People who have had a serious injury, serious infection, or surgery in the 12 weeks before screening that may have affected their blood sugar levels.
  • People who have received a blood transfusion in the 12 weeks before screening, or who have donated or lost a significant amount of blood in the weeks before screening, or who have a known inherited blood condition such as thalassemia, sickle cell anaemia, or a condition causing the breakdown of red blood cells.
  • People who have any other hormone-related condition (apart from type 2 diabetes) that is unstable or being treated and affects blood sugar levels, such as an overactive thyroid, Cushing's syndrome, or acromegaly.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026

Contact this trial

Phone: 88326666

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
31 August 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov